TY - JOUR
T1 - Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms
T2 - Inhibiting viral replication and decreasing viral entry
AU - Yang, Shu
AU - Xu, Miao
AU - Lee, Emily M.
AU - Gorshkov, Kirill
AU - Shiryaev, Sergey A.
AU - He, Shihua
AU - Sun, Wei
AU - Cheng, Yu Shan
AU - Hu, Xin
AU - Tharappel, Anil Mathew
AU - Lu, Billy
AU - Pinto, Antonella
AU - Farhy, Chen
AU - Huang, Chun Teng
AU - Zhang, Zirui
AU - Zhu, Wenjun
AU - Wu, Yuying
AU - Zhou, Yi
AU - Song, Guang
AU - Zhu, Heng
AU - Shamim, Khalida
AU - Martínez-Romero, Carles
AU - García-Sastre, Adolfo
AU - Preston, Richard A.
AU - Jayaweera, Dushyantha T.
AU - Huang, Ruili
AU - Huang, Wenwei
AU - Xia, Menghang
AU - Simeonov, Anton
AU - Ming, Guoli
AU - Qiu, Xiangguo
AU - Terskikh, Alexey V.
AU - Tang, Hengli
AU - Song, Hongjun
AU - Zheng, Wei
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The re-emergence of Zika virus (ZIKV) and Ebola virus (EBOV) poses serious and continued threats to the global public health. Effective therapeutics for these maladies is an unmet need. Here, we show that emetine, an anti-protozoal agent, potently inhibits ZIKV and EBOV infection with a low nanomolar half maximal inhibitory concentration (IC50) in vitro and potent activity in vivo. Two mechanisms of action for emetine are identified: the inhibition of ZIKV NS5 polymerase activity and disruption of lysosomal function. Emetine also inhibits EBOV entry. Cephaeline, a desmethyl analog of emetine, which may be better tolerated in patients than emetine, exhibits a similar efficacy against both ZIKV and EBOV infections. Hence, emetine and cephaeline offer pharmaceutical therapies against both ZIKV and EBOV infection.
AB - The re-emergence of Zika virus (ZIKV) and Ebola virus (EBOV) poses serious and continued threats to the global public health. Effective therapeutics for these maladies is an unmet need. Here, we show that emetine, an anti-protozoal agent, potently inhibits ZIKV and EBOV infection with a low nanomolar half maximal inhibitory concentration (IC50) in vitro and potent activity in vivo. Two mechanisms of action for emetine are identified: the inhibition of ZIKV NS5 polymerase activity and disruption of lysosomal function. Emetine also inhibits EBOV entry. Cephaeline, a desmethyl analog of emetine, which may be better tolerated in patients than emetine, exhibits a similar efficacy against both ZIKV and EBOV infections. Hence, emetine and cephaeline offer pharmaceutical therapies against both ZIKV and EBOV infection.
UR - http://www.scopus.com/inward/record.url?scp=85048122680&partnerID=8YFLogxK
U2 - 10.1038/s41421-018-0034-1
DO - 10.1038/s41421-018-0034-1
M3 - Article
AN - SCOPUS:85048122680
SN - 2056-5968
VL - 4
JO - Cell Discovery
JF - Cell Discovery
IS - 1
M1 - 31
ER -